BioRestorative Therapies Unveils $1.085 Million Registered Direct Offering at a Premium Price
Company Announcement: BioRestorative Therapies, Inc. has entered into agreements to sell 678,125 shares of common stock at $1.60 per share, alongside issuing unregistered warrants for additional shares, aiming to raise approximately $1.085 million for clinical trials and research.
Use of Proceeds: The funds will support the clinical trials for their lead therapy candidate BRTX-100, pre-clinical research for the ThermoStem® Program, and the development of their biocosmeceuticals platform, as well as general corporate purposes.
Clinical Development Programs: BioRestorative focuses on two main programs: the BRTX-100 for treating disc/spine diseases and the ThermoStem® for addressing obesity and metabolic disorders through stem cell therapies.
Forward-Looking Statements: The press release includes forward-looking statements that are subject to risks and uncertainties, advising caution in relying on these projections as they may differ from actual future results.
Trade with 70% Backtested Accuracy
Analyst Views on BRTX
No data
About BRTX
About the author
Novo Nordisk (NVO) Gains 9.48% After FDA Approves Wegovy Obesity Pill
- FDA Approval Milestone: Novo Nordisk's once-daily Wegovy obesity pill received FDA approval, leading to a 9.48% increase in after-hours trading to $52.66, marking a significant advancement in obesity treatment that is expected to drive sales growth and enhance market competitiveness.
- Cardiovascular Risk Reduction: Wegovy is not only indicated for weight loss but also approved to reduce the risk of major cardiovascular events in obese patients, which will likely attract more patients with related conditions, thereby expanding the potential market.
- Rising Investor Interest: Despite no new updates, Neumora Therapeutics and BioRestorative Therapies saw increases of 16.02% and 6.90% respectively, indicating broad investor interest and optimism in the biotech sector, which may fuel a wave of investment across the industry.
- Clinical Trial Progress: IDEAYA Biosciences announced full enrollment of 435 patients in its Phase 2/3 trial, with progression-free survival data expected in Q1 2026, potentially paving the way for accelerated approval in the U.S. and further solidifying the company's position in cancer treatment.
NOTV and APLT Top After-Hours Biotech Gains; ALMS, TELA, CORT, and BRTX Also Show Progress
Biotech Gains in After-Hours Trading: Several small-cap biotech companies saw significant stock price increases in after-hours trading, driven by earnings updates and regulatory news.
Inotiv, Inc. Performance: Inotiv, Inc. experienced a 36.61% surge to $0.94 after announcing preliminary Q4 and full-year 2025 revenue projections, recovering from a prior decline.
Applied Therapeutics and Alumis Updates: Applied Therapeutics rose 16.89% following a positive earnings report, while Alumis advanced 7.09% despite a wider Q3 net loss, supported by collaboration income.
Regulatory Developments for BioRestorative: BioRestorative Therapies gained 8.06% after announcing a meeting with the FDA to discuss a potential accelerated pathway for its treatment of chronic lumbar disc disease.
Transcript of BioRestorative (BRTX) Earnings Call
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Biorestorative Therapies, Inc. (BRTX) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Biorestorative Therapies, Inc. (BRTX) reported a quarterly loss of $0.38 per share, matching expectations but worsening from a loss of $0.13 per share a year ago, with revenues significantly missing estimates at $0.01 million.
Stock Outlook: The company's stock has underperformed, losing about 1.4% this year compared to the S&P 500's 16.4% gain, and currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.28 on $0.5 million in revenues, while the current fiscal year estimate is -$1.55 on $1.23 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Biorestorative operates within the Medical - Biomedical and Genetics industry, which ranks in the top 34% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
InflaRx N.V. Surge: InflaRx N.V. saw a significant after-hours increase of 63.41% to $2.01, driven by the anticipation of topline data from its Phase 2a trial and third-quarter financial results expected on Monday.
Rallybio Corp. Performance: Rallybio Corp. rose 12.84% to $0.71 after reporting a third-quarter net income of $16.0 million, reversing a loss from the previous year, although revenue slightly declined.
FibroBiologics Inc. Growth: FibroBiologics Inc. climbed 13.51% to $0.40 after hours, following a previous corporate update and third-quarter financial results released on October 31.
Cellectis S.A. Recovery: Cellectis S.A. increased by 6.58% to $3.40 after reporting a third-quarter net income of $589 thousand, a significant improvement from a loss in the prior year, with revenues more than doubling.
BioRestorative's CEO Lance Alstodt Featured on "The Big Biz Show"
Company Overview: BioRestorative Therapies, Inc. is a regenerative medicine company focused on stem cell-based therapies, with key programs targeting disc/spine diseases and metabolic disorders.
CEO Interview: CEO Lance Alstodt discussed the company's recent clinical and regulatory achievements in an interview on "The Big Biz Show," which will be aired across various platforms globally.
Novo Nordisk (NVO) Gains 9.48% After FDA Approves Wegovy Obesity Pill
- FDA Approval Milestone: Novo Nordisk's once-daily Wegovy obesity pill received FDA approval, leading to a 9.48% increase in after-hours trading to $52.66, marking a significant advancement in obesity treatment that is expected to drive sales growth and enhance market competitiveness.
- Cardiovascular Risk Reduction: Wegovy is not only indicated for weight loss but also approved to reduce the risk of major cardiovascular events in obese patients, which will likely attract more patients with related conditions, thereby expanding the potential market.
- Rising Investor Interest: Despite no new updates, Neumora Therapeutics and BioRestorative Therapies saw increases of 16.02% and 6.90% respectively, indicating broad investor interest and optimism in the biotech sector, which may fuel a wave of investment across the industry.
- Clinical Trial Progress: IDEAYA Biosciences announced full enrollment of 435 patients in its Phase 2/3 trial, with progression-free survival data expected in Q1 2026, potentially paving the way for accelerated approval in the U.S. and further solidifying the company's position in cancer treatment.
NOTV and APLT Top After-Hours Biotech Gains; ALMS, TELA, CORT, and BRTX Also Show Progress
Biotech Gains in After-Hours Trading: Several small-cap biotech companies saw significant stock price increases in after-hours trading, driven by earnings updates and regulatory news.
Inotiv, Inc. Performance: Inotiv, Inc. experienced a 36.61% surge to $0.94 after announcing preliminary Q4 and full-year 2025 revenue projections, recovering from a prior decline.
Applied Therapeutics and Alumis Updates: Applied Therapeutics rose 16.89% following a positive earnings report, while Alumis advanced 7.09% despite a wider Q3 net loss, supported by collaboration income.
Regulatory Developments for BioRestorative: BioRestorative Therapies gained 8.06% after announcing a meeting with the FDA to discuss a potential accelerated pathway for its treatment of chronic lumbar disc disease.
Transcript of BioRestorative (BRTX) Earnings Call
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Biorestorative Therapies, Inc. (BRTX) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Biorestorative Therapies, Inc. (BRTX) reported a quarterly loss of $0.38 per share, matching expectations but worsening from a loss of $0.13 per share a year ago, with revenues significantly missing estimates at $0.01 million.
Stock Outlook: The company's stock has underperformed, losing about 1.4% this year compared to the S&P 500's 16.4% gain, and currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.28 on $0.5 million in revenues, while the current fiscal year estimate is -$1.55 on $1.23 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Biorestorative operates within the Medical - Biomedical and Genetics industry, which ranks in the top 34% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
InflaRx N.V. Surge: InflaRx N.V. saw a significant after-hours increase of 63.41% to $2.01, driven by the anticipation of topline data from its Phase 2a trial and third-quarter financial results expected on Monday.
Rallybio Corp. Performance: Rallybio Corp. rose 12.84% to $0.71 after reporting a third-quarter net income of $16.0 million, reversing a loss from the previous year, although revenue slightly declined.
FibroBiologics Inc. Growth: FibroBiologics Inc. climbed 13.51% to $0.40 after hours, following a previous corporate update and third-quarter financial results released on October 31.
Cellectis S.A. Recovery: Cellectis S.A. increased by 6.58% to $3.40 after reporting a third-quarter net income of $589 thousand, a significant improvement from a loss in the prior year, with revenues more than doubling.
BioRestorative's CEO Lance Alstodt Featured on "The Big Biz Show"
Company Overview: BioRestorative Therapies, Inc. is a regenerative medicine company focused on stem cell-based therapies, with key programs targeting disc/spine diseases and metabolic disorders.
CEO Interview: CEO Lance Alstodt discussed the company's recent clinical and regulatory achievements in an interview on "The Big Biz Show," which will be aired across various platforms globally.
